Recently awarded Fast Track status by the U.S. Food and Drug Administration (FDA), BriaCell is developing Bria-IMT™ in combination with immune checkpoint inhibitors in a clinical trial listed in ClinicalTrials.gov as NCT03328026. BriaCell is currently enrolling and dosing advanced breast cancer patients in its Phase I/II combination study of Bria-IMT™ with Incyte’s checkpoint inhibitor, retifanlimab, and its immunomodulator, epacadostat under a corporate collaboration with Incyte.
About Bria-IMT™ (SV-BR-1-GM)
Developed and characterized by a team of dedicated scientists and clinicians, Bria-IMT™ (SV-BR-1-GM) is a targeted immunotherapy being developed for the treatment of advanced breast cancer (i.e. breast cancer that has spread from the breast or armpit to other areas of the body including the bones, lungs, liver or sometimes the brain). Bria-IMT™ is a genetically engineered human breast cancer cell line with features of immune cells. It is clinically used as a targeted immunotherapy.
Mechanism of Action of Bria-IMT™: The mechanism of action of Bria-IMT™ is currently under investigation. We hypothesize that Bria-IMT™ both indirectly and directly stimulates the body’s own cancer-fighting cells to attack and destroy breast cancer tumors. INDIRECTLY, Bria-IMT™ produces breast cancer “antigens” (proteins that are expressed in breast cancer cells) that are then recognized by the immune system, which can then recognize those same antigens in a patient’s breast cancer and attack the cancer. In addition, Bria-IMT™ appears to be able to DIRECTLY stimulate these cancer-fighting immune cells markedly, boosting the body’s response.
We believe that Bria-IMT™:
- Produces antigens (proteins made by breast cancer cells).
- Further boosts the immune response through secretion of a protein called GM-CSF.
- “Presents” the antigens to CD4+ and CD8+ T-cells, cells known for tumor destruction.
- Also directly stimulates cancer-fighting T-cells, further boosting the response.
Using BriaCell’s novel technology platform and our strong R&D capabilities, we plan to develop immunotherapies for other cancer indications.